What does a Hepatitis B Surface Antibody (HBsAb) level of 0.53 IU/L imply?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Interpretation of Hepatitis B Surface Antibody Level of 0.53 IU/L

A Hepatitis B Surface Antibody (anti-HBs) level of 0.53 IU/L indicates that this 39-year-old female is not immune to hepatitis B virus infection and requires vaccination.

Understanding Anti-HBs Levels and Immunity

  • Anti-HBs levels ≥10 mIU/mL (or ≥10 IU/L) are considered protective against HBV infection according to established guidelines 1
  • The patient's level of 0.53 IU/L falls significantly below this protective threshold, indicating lack of immunity 1, 2
  • This result pattern suggests the patient has never been infected with HBV and has not been successfully vaccinated 3

Clinical Implications

  • The patient is susceptible to HBV infection and should receive the complete hepatitis B vaccination series 3
  • Without adequate anti-HBs levels, the patient has no protection against potential HBV exposure 1
  • This serologic pattern (negative HBsAg, negative anti-HBc, anti-HBs <10 mIU/mL) is consistent with a person who is either:
    • Never vaccinated against hepatitis B 3
    • Previously vaccinated but did not develop adequate antibody response 3
    • Previously vaccinated but antibody levels have waned below protective levels 4

Recommended Management

Primary Vaccination Series

  • Administer the complete hepatitis B vaccine series following the standard schedule (0,1, and 6 months) 3
  • Alternative accelerated schedules include 0,1, and 4 months or 0,2, and 4 months 3
  • For adults, the standard dose is 20 μg per dose for Engerix-B or 10 μg per dose for Recombivax HB 3

Post-Vaccination Testing

  • Perform post-vaccination serologic testing 1-2 months after completing the vaccine series 3
  • Test for anti-HBs to confirm development of protective immunity (≥10 mIU/mL) 3, 1

Non-Responders Management

  • If anti-HBs remains <10 mIU/mL after primary series, administer a second complete 3-dose series 3
  • Test for anti-HBs 1-2 months after completion of the second series 3
  • For persistent non-responders after two complete series, consider them susceptible to HBV infection and counsel accordingly 3

Special Considerations

  • If the patient works in healthcare or has other occupational risks, post-vaccination testing is particularly important 3
  • For healthcare personnel with documented vaccination but unknown antibody response, test for anti-HBs upon hire; if <10 mIU/mL, provide one dose of HepB vaccine followed by anti-HBs testing 3
  • Immunocompromised individuals may require higher vaccine doses or additional doses to achieve protective immunity 3

Common Pitfalls to Avoid

  • Don't confuse anti-HBs with HBsAg; the former indicates immunity while the latter indicates active infection 5
  • Don't assume that a low but detectable anti-HBs level provides any protection; levels must be ≥10 mIU/mL 1, 2
  • Be aware that passively acquired anti-HBs (from hepatitis B immune globulin or blood products) can create false impression of immunity 6
  • Don't assume that once protective, immunity lasts forever; anti-HBs levels can wane over time, though immune memory often persists in immunocompetent individuals 4, 7

References

Guideline

Interpretation of Hepatitis B Panel Results

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Hepatitis B Immunity and Serologic Test Interpretation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Hepatitis B Surface Antigen Testing

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Increases in levels of antibody to hepatitis B surface antigen in an immunized population.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1998

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.